Lilly is in focus amid claims that weight-loss drugs are becoming an alternative to the gym. What do the latest company news and financials suggest about demand and the potential market impact, and how should investors separate evidence from hype?
Zepbound’s first inclusion in US Medicare coverage is raising expectations for higher demand. What could determine the effect on Lilly’s sales, and what details should investors watch as coverage expands?